与标准化疗相比,吉非替尼用于敏感性EGFR突变(外显子19del、外显子21L858R简称L858R)晚期NSCLC患者的一线治疗可以延长患者的无进展生存期(progression-free survival, PFS)(吉非替尼vs化疗,中位PFS:10.8个月vs 5.4个月)和总生存期(overall survival, OS)(OS:30.5个月vs 23.6个月),其安全性好,毒性可耐受——其最常见的不良事件(adverse event, AE)为皮疹(71.1%)、转氨酶升高(55.3%)及腹泻(46.6%)[23, 24]。. Here, EGFR is linked to non-small cell lung carcinoma.